202 related articles for article (PubMed ID: 28451831)
21. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
22. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
23. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.
Leamon CP; Reddy JA; Vlahov IR; Kleindl PJ; Vetzel M; Westrick E
Bioconjug Chem; 2006; 17(5):1226-32. PubMed ID: 16984132
[TBL] [Abstract][Full Text] [Related]
26. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of a new modular nanotransporter for drug delivery into nuclei of pathological cells expressing folate receptors.
Slastnikova TA; Rosenkranz AA; Khramtsov YV; Karyagina TS; Ovechko SA; Sobolev AS
Drug Des Devel Ther; 2017; 11():1315-1334. PubMed ID: 28490863
[TBL] [Abstract][Full Text] [Related]
28. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Dawson A; Dorton R; Vetzel M; Santhapuram HK; Wang Y
Mol Pharm; 2007; 4(5):659-67. PubMed ID: 17874843
[TBL] [Abstract][Full Text] [Related]
29. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
30. [18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting.
Fischer CR; Müller C; Reber J; Müller A; Krämer SD; Ametamey SM; Schibli R
Bioconjug Chem; 2012 Apr; 23(4):805-13. PubMed ID: 22372827
[TBL] [Abstract][Full Text] [Related]
31. Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
Péraudeau E; Cronier L; Monvoisin A; Poinot P; Mergault C; Guilhot F; Tranoy-Opalinski I; Renoux B; Papot S; Clarhaut J
J Control Release; 2018 Jan; 269():36-44. PubMed ID: 29129656
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
33. Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand.
Wayua C; Roy J; Putt KS; Low PS
Mol Pharm; 2015 Jul; 12(7):2477-83. PubMed ID: 26043355
[TBL] [Abstract][Full Text] [Related]
34. Comparative Studies of Three Pairs of α- and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18.
Boss SD; Betzel T; Müller C; Fischer CR; Haller S; Reber J; Groehn V; Schibli R; Ametamey SM
Bioconjug Chem; 2016 Jan; 27(1):74-86. PubMed ID: 26634288
[TBL] [Abstract][Full Text] [Related]
35. A new 18F-labeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors.
Ross TL; Honer M; Müller C; Groehn V; Schibli R; Ametamey SM
J Nucl Med; 2010 Nov; 51(11):1756-62. PubMed ID: 20956469
[TBL] [Abstract][Full Text] [Related]
36. Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys.
Chu H; Shillingford JM; Reddy JA; Westrick E; Nelson M; Wang EZ; Parker N; Felten AE; Vaughn JF; Xu LC; Lu YJ; Vlahov IR; Leamon CP
Mol Pharm; 2019 Sep; 16(9):3985-3995. PubMed ID: 31356752
[TBL] [Abstract][Full Text] [Related]
37. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides.
Vlahov IR; Wang Y; Kleindl PJ; Leamon CP
Bioorg Med Chem Lett; 2008 Aug; 18(16):4558-61. PubMed ID: 18657420
[TBL] [Abstract][Full Text] [Related]
38. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
[TBL] [Abstract][Full Text] [Related]
39. Targeting folate receptors to treat invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Naughton JF; Cheng L; Low PS; Rothenbuhler R; Leamon CP; Parker N; Klein PJ; Vlahov IR; Reddy JA; Koch M; Murphy L; Fourez LM; Stewart JC; Knapp DW
Cancer Res; 2013 Jan; 73(2):875-84. PubMed ID: 23204225
[TBL] [Abstract][Full Text] [Related]
40. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
